BEGIN:VCALENDAR VERSION:2.0 PRODID:-//ZContent.net//ZapCalLib 1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH BEGIN:VEVENT SUMMARY:Arrowhead Pharmaceuticals, Inc. Information Session LOCATION:Virtual TZID:America/Denver DTSTART:20220118T100000 UID:2026-04-03-21-16-35@natsci.colostate.edu DTSTAMP:20260403T211635 Description:Presenters:\n\nErich Altenhofer\, Sr. Chemist\, CMC Process Che mistry\, Arrowhead Pharmaceuticals\, Inc.\, Madison\, WI.\n\nTania Mutchie \, Sr. Scientist\, Developmental Chemistry\, Arrowhead Pharmaceuticals\, I nc.\, Madison\, WI.\n\nTrevor Nykaza\, Sr. Chemist\, Developmental Chemist ry\, Arrowhead Pharmaceuticals\, Inc.\, Madison\, WI.\n\n \;\n\nJoin Z oom Meeting\n\nhttps://arrowheadpharma.zoom.us/j/89923042988?pwd=TU8rUG1uR VhrYTFldUVja0VXZkhiZz09\n\nMeeting ID: 899 2304 2988\n\nPasscode: 624957\n \nOne tap mobile\n\n+16699006833\,\,89923042988#\,\,\,\,*624957# US (San J ose)\n\n+12532158782\,\,89923042988#\,\,\,\,*624957# US (Tacoma)\n\nDial b y your location\n\n+1 669 900 6833 US (San Jose)\n\n+1 253 215 8782 US (Ta coma)\n\n+1 346 248 7799 US (Houston)\n\n+1 312 626 6799 US (Chicago)\n\n+ 1 929 205 6099 US (New York)\n\n+1 301 715 8592 US (Washington DC)\n\nMeet ing ID: 899 2304 2988\n\nPasscode: 624957\n\nFind your local number: http s://arrowheadpharma.zoom.us/u/kbr4AVJ10d\n\nJoin by Skype for Business: ht tps://arrowheadpharma.zoom.us/skype/89923042988\n\n \;\n\nArrowhead Ph armaceuticals\, Inc. (Nasdaq: ARWR) is a clinical stage biopharmaceutical company that develops medicines that treat intractable diseases by silenci ng the genes that cause them. Using a broad portfolio of RNA chemistries a nd efficient modes of delivery\, Arrowhead therapies trigger the RNA inter ference mechanism to induce rapid\, deep\, and durable knockdown of target genes. RNA interference\, or RNAi\, is a mechanism present in living cell s that inhibits the expression of a specific gene\, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics le verage this natural pathway of gene silencing.\n\nArrowhead is focused on developing innovative drugs for diseases with a genetic basis\, typically characterized by the overproduction of one or more proteins that are invol ved with disease. The depth and versatility of our RNAi technologies enabl es us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small mol ecules and biologics. Arrowhead is leading the field in bringing the promi se of RNAi to address diseases outside of the liver\, and our clinical pip eline includes disease targets in the liver\, lung\, and solid tumors with a promising pipeline of preclinical candidates.\n\nArrowhead’s corporat e headquarters\, commercial\, clinical and regulatory teams are in Pasaden a\, CA with research and development teams in Madison\, WI and San Diego\, CA. Our employees are nimble\, science-driven innovators who are collabor ating to bring new therapies to patients in need.10:00 am END:VEVENT END:VCALENDAR